title: Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy.
abstract: Hemifacial spasm (HFS) is a chronic movement disorder which presents as clonic and/or tonic facial muscle contractions frequently accompanied by many other sensory (visual or auditory disturbances, pain), motor (facial weakness, trismus, bruxism, dysarthria) and/or autonomic (lacrimation, salivation) symptoms. The aim of the study was to assess the occurrence of HFS non-motor and motor-related symptoms and their responsiveness to botulinum toxin type A (BTX-A) therapy. 56 HFS patients were included in the open-label design study. Patients were examined three times: before BTX-A injection, and 2 and 12 weeks later. The occurrence of non-motor and motor-related symptoms was assessed by a special questionnaire, and the severity of HFS was rated by the Clinical Global Impression-Severity scale (CGI-S) and depression symptoms by the Beck Depression Inventory (BDI). Over 81% of the patients before BTX-A therapy reported HFS non-motor and motor-related symptoms. Almost 50% of the patients reported more than three symptoms. The most frequent symptoms were: tearing (44.5%), eye irritation (39.3%), facial paraesthesia (26.8%) and hearing of a "clicking" sound (25.0%). 2 weeks after BTX-A injection 75% of the patients did not report any symptoms and 20% reported only one or two. 3 months later the number of symptoms had increased again, with 57% of patients reporting at least one. The number of HFS non-motor and other symptoms did not correlate with the patients' age, disease duration and the presence of neuro-vascular conflict, but were positively correlated with the CGI-S and BDI scores. This study showed that muscle contractions in HFS patients are commonly accompanied by non-motor and other motor-related symptoms and most of them are reduced following BTX-A treatment.
authors.affiliation: Department of Neurology, Jagiellonian University Medical College, 3 Botaniczna Str., 31-503 Kraków, Poland. rudzinsk@cm-uj.krakow.pl
authors.forename: Monika
authors.initials: M
authors.lastname: Rudzińska
authors.forename: Magdalena
authors.initials: M
authors.lastname: Wójcik
authors.forename: Andrzej
authors.initials: A
authors.lastname: Szczudlik
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D005260:Female; D019569:Hemifacial Spasm / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A
references.citation: Eur J Neurol. 2006 Feb;13 Suppl 1:30-5
references.pmid: 16417595
references.citation: Brain. 1985 Sep;108 ( Pt 3):593-608
references.pmid: 4041776
references.citation: Mov Disord. 2004 Mar;19 Suppl 8:S137-41
references.pmid: 15027066
references.citation: Mov Disord. 1998 Jan;13(1):108-17
references.pmid: 9452335
references.citation: Acta Neurol Scand. 2005 Jan;111(1):64-70
references.pmid: 15595940
references.citation: Am J Ophthalmol. 1990 Oct 15;110(4):421-3
references.pmid: 2220979
references.citation: Rev Clin Esp. 1991 Nov;189(7):320-4
references.pmid: 1767088
references.citation: Arch Neurol. 1990 Nov;47(11):1233-4
references.pmid: 2241620
references.citation: Mov Disord. 2004 Mar;19 Suppl 8:S60-4
references.pmid: 15027056
references.citation: Muscle Nerve. 1991 Jul;14(7):672-5
references.pmid: 1922173
references.citation: Surg Neurol. 1991 Oct;36(4):251-77
references.pmid: 1948626
references.citation: Clin Neurol Neurosurg. 2008 Sep;110(8):813-7
references.pmid: 18583029
references.citation: Muscle Nerve. 1998 Dec;21(12):1740-7
references.pmid: 9843077
references.citation: J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):951-7
references.pmid: 15201348
references.citation: J Neurosurg. 1984 Sep;61(3):569-76
references.pmid: 6086858
references.citation: Health Qual Life Outcomes. 2009 Dec 24;7:104
references.pmid: 20034399
references.citation: Acta Neurochir (Wien). 1994;126(2-4):149-57
references.pmid: 8042548
references.citation: Wien Klin Wochenschr. 1999 Jan 29;111(2):59-65
references.pmid: 10081123
references.citation: J Neurol Neurosurg Psychiatry. 1991 Apr;54(4):310-3
references.pmid: 1647444
references.citation: J Neurol Sci. 2004 Apr 15;219(1-2):151-5
references.pmid: 15050451
references.citation: Mov Disord. 1992;7(2):181-4
references.pmid: 1584239
references.citation: J Neurol Neurosurg Psychiatry. 2004 Mar;75(3):494-6
references.pmid: 14966174
references.citation: J Neurosurg. 1985 Jul;63(1):17-20
references.pmid: 4009269
references.citation: Parkinsonism Relat Disord. 2005 Jun;11(4):241-5
references.pmid: 15878585
references.citation: Neurology. 1984 Apr;34(4):418-26
references.pmid: 6322048
references.citation: J Neurol Sci. 1991 Jan;101(1):114-23
references.pmid: 2027024
references.citation: Postgrad Med J. 1973 Oct;49(576):742-5
references.pmid: 4786441
references.citation: Mov Disord. 1993;8(1):33-7
references.pmid: 8380486
references.citation: Mov Disord. 1999 Sep;14(5):832-5
references.pmid: 10495046
references.citation: J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):979-81
references.pmid: 12810800
references.citation: J Neurol Neurosurg Psychiatry. 1998 Jun;64(6):751-7
references.pmid: 9647304
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1976;292(2):161-5
references.pmid: 59905
references.citation: Ann Otol Rhinol Laryngol. 2000 Feb;109(2):194-203
references.pmid: 10685573
references.citation: Clin Neurosurg. 1968;15:1-56
references.pmid: 4945158
references.citation: Neurology. 1996 Apr;46(4):1158-60
references.pmid: 8780112